Tanvex BioPharma and TaiMed Biologics jointly announced on June 14, 2022 to form a business alliance to offer CDMO services in the development and manufacturing of Antibody-Drug Conjugates (ADC) and Bispecific Antibodies (BsAb). Both companies already have full R&D and CDMO capabilities. Leveraging both parties'experienced R&D teams, advanced technologies, and GMP manufacturing facilities, the alliance will be able to offer high-quality CDMO services at competitive pricing from bench to commercialization.

This business alliance will synergistically unleash both companies' capabilities and capacities to the next level. In this arrangement, Tanvex will focus on the initial stage of gene sequencing, cell line development, and process development; TaiMed will focus on technology transfer, scale-up, and full scale manufacturing and testing.